Abstract
Neurological disorders encompass multifaceted and heterogeneous ailments that influence the whole body though the central and peripheral nervous systems. These conditions give rise to a variety of incapacitating symptoms, thereby exerting an important impact on the overall well-being of countless individuals across the globe. This book chapter provides an overview of the complex realm of neurological disorders and the formidable obstacles they present within the framework of theranostics, with the objective of tailoring personalized treatment. The foremost common neurological disorders will be covered, including but not limited to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and epilepsy, accentuating their clinical pathophysiology and the profound onus they impose upon patients, carers, and healthcare systems. For timely identification of disease onset and precise categorization, diagnostic methodologies will be included, encompassing neuroimaging, cerebrospinal fluid biomarkers, and genetic profiling. However, the obstacles encountered in the development of efficacious theranostic strategies for neurological disorders will also be mentioned (e.g., drug delivery across the blood-brain barrier). The elucidation of emerging technologies, including nanomedicine, gene therapy, and precision medicine, presents promising avenues for surmounting these challenges and heralding a novel epoch of personalized therapeutics. By establishing a connection between diagnosis and treatment, researchers and clinicians can strive to offer more effective interventions to address the complex nature of neurological disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abboud H et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92(7):757–768
Abraham R (2013) Steroids in neuroinfection. Arq Neuropsiquiatr 71(9 B):717–721. https://doi.org/10.1590/0004-282X20130158
Acharya KP et al (2020) One-health approach: a best possible way to control rabies. One Health 10:100161
Adams Y, Jensen AR (2022) Cerebral malaria–modelling interactions at the blood–brain barrier in vitro. Dis Model Mech 15(7):dmm049410
Ahmad Mir F, Amanullah A, Prakash Jain B, Hyderi Z, Gautam A (2023) Neuroepigenetics of ageing and neurodegeneration-associated dementia: an updated review. Ageing Res Rev 91:102067. https://doi.org/10.1016/j.arr.2023.102067
Al-Hassany L et al (2023) Future targets for migraine treatment beyond CGRP. J Headache Pain 24(1):76
Amorín I et al (2023) National stroke management plan in Uruguay: challenges and opportunities. Front Neurol 13:973380
Attfield KE et al (2022) The immunology of multiple sclerosis. Nat Rev Immunol 22(12):734–750
Autier B et al (2023) Alveolar echinococcosis in immunocompromised hosts. Clin Microbiol Infect 29(5):593–599
Aziz NA et al (2022) Type 2 immunity: a two-edged sword in schistosomiasis immunopathology. Trends Immunol 43(8):657–673
Bernhard S et al (2022) Fexinidazole for human African trypanosomiasis, the fruit of a successful public-private partnership. Diseases 10(4):90
Bloem BR et al (2021) Parkinson’s disease. Lancet 397(10291):2284–2303
Boffeli TJ, Guze SB (1992) The simulation of neurologic disease. Psychiatr Clin 15(2):301–310
Bowers KM, Mudrakola VV (2020) Neuroinfections: presentation, diagnosis, and treatment of meningitis and encephalitis. Eur Med J. https://doi.org/10.33590/emjneurol/20-00063
Brenner D, Freischmidt A (2022) Update on genetics of amyotrophic lateral sclerosis. Curr Opin Neurol 35(5):672–677
Chavhan PV et al (2023) Technology based interventions for Tourette’s syndrome—a brief review. Int J Indian Psychȯl 11(2):2965–2973
Chou C-Y et al (2023) Emerging therapies and recent advances for Tourette syndrome. Heliyon 9:e12874
Cruccu G (2007) Treatment of painful neuropathy. Curr Opin Neurol 20(5):531–535
Danics K, Forrest SL, Kapas I, Erber I, Schmid S, Törő K, Majtenyi K, Kovacs GG (2021) Neurodegenerative proteinopathies associated with neuroinfections. J Neural Transm 128(10):1551–1566. https://doi.org/10.1007/S00702-021-02371-7/TABLES/5
Daskalakis NP, Bagot RC, Parker KJ, Vinkers CH, de Kloet ER, Peters JJ (2013) The three-hit concept of vulnerability and resilience: towards understanding adaptation to early-life adversity outcome. Psychoneuroendocrinology 38(9):1858–1873. https://doi.org/10.1016/j.psyneuen.2013.06.008
Del Brutto OH (2022) Human neurocysticercosis: an overview. Pathogens 11(10):1212
Díaz AV et al (2023) Reaching the World Health Organization elimination targets for schistosomiasis: the importance of a One Health perspective. Philos Trans R Soc B 378(1887):20220274
Dubois B et al (2021) Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol 20(6):484–496
Engel GL (1978) The biopsychosocial model and the education of health professionals. Ann N Y Acad Sci 310:169–187
Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, LaFaver K, LaFrance WC Jr, Lang AE, Nicholson T, Nielsen G, Reuber M, Voon V, Stone J, Morgante F (2018) Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 75(9):1132–1141. https://doi.org/10.1001/jamaneurol.2018.1264. PMID: 29868890; PMCID: PMC7293766
Feldman EL et al (2022) Amyotrophic lateral sclerosis. Lancet 400(10360):1363–1380
Galiero R et al (2023) Peripheral neuropathy in diabetes mellitus: pathogenetic mechanisms and diagnostic options. Int J Mol Sci 24(4):3554
Gilhus NE, Deuschl G (2019) Neuroinflammation—a common thread in neurological disorders. Nat Rev Neurol 15(8):429–430
Glatt SJ, Faraone SV, Tsuang MT (2019) Is schizophrenia a neurodevelopmental disorder? Schizophrenia. https://doi.org/10.1093/OSO/9780198813774.003.0014
Gold S et al (2020) Rabies virus-neutralising antibodies in healthy, unvaccinated individuals: what do they mean for rabies epidemiology? PLoS Negl Trop Dis 14(2):e0007933
Grover S, Chakrabarti S, Kulhara P, Avasthi A (2017) Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry 59(Suppl 1):S19. https://doi.org/10.4103/0019-5545.196972
Hallett M et al (2022) Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol 21(6):537–550
Hamer SA, Saunders AB (2022) Veterinary Chagas disease (American Trypanosomiasis) in the United States. Vet Clin North Am Small Anim Pract 52(6):1267–1281
Hasbun R (2022) Progress and challenges in bacterial meningitis: a review. JAMA 328(21):2147–2154
Hauser SL, Cree BA (2020) Treatment of multiple sclerosis: a review. Am J Med 133(12):1380–1390.e1382
Heidenreich M, Zhang F (2016) Applications of CRISPR–Cas systems in neuroscience. Nat Rev Neurosci 17(1):36–44
Ilieva H, Vullaganti M, Kwan J, Weinberg J, Center A (2023) State of the art review. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ. https://doi.org/10.1136/bmj-2023-075037
Ismail CAN (2023) Issues and challenges in diabetic neuropathy management: a narrative review. World J Diabetes 14(6):741–757
Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795–808
Johnson SA et al (2022) Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents. Drugs 82(13):1367–1388
Jorgačevski J, Potokar M (2023) Immune functions of astrocytes in viral neuroinfections. Int J Mol Sci 24(4):3514. https://doi.org/10.3390/IJMS24043514
Kamei S (2021) Practical progression in the clinical management of neuroinfections and related diseases in Japan. Neurol Clin Neurosci 9(1):45–49. https://doi.org/10.1111/NCN3.12442
Kampmann M (2020) CRISPR-based functional genomics for neurological disease. Nat Rev Neurol 16(9):465–480
Kilarski LL et al (2012) Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord 27(12):1522–1529
Kukkar A, Bali A, Singh N, Jaggi AS (2013) Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 36(3):237–251. https://doi.org/10.1007/S12272-013-0057-Y
La Rovere M et al (2019) Epigenetics and neurological disorders in ART. Int J Mol Sci 20(17):4169
Lamanna J et al (2023) The dysfunctional mechanisms throwing tics: structural and functional changes in Tourette syndrome. Behav Sci 13(8):668
László K, Vörös D, Correia P, Fazekas CL, Török B, Plangár I, Zelena D (2023) Vasopressin as possible treatment option in autism spectrum disorder. Biomedicines. https://doi.org/10.3390/biomedicines11102603
Lee MJ et al (2023) New migraine prophylactic drugs: current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia 43(2):03331024221146315
Lejman J, Panuciak K, Nowicka E, Mastalerczyk A, Wojciechowska K, Lejman M (2023) Gene therapy in ALS and SMA: advances, challenges and perspectives. Int J Mol Sci 24(2):1130. https://doi.org/10.3390/ijms24021130
Leonhard SE et al (2019) Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol 15(11):671–683
Li T et al (2022) Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J Control Release 352:338–370
Liu G et al (2017) Epilepsy: treatment options. Am Fam Physician 96(2):87–96
Ma ZL, Wang ZL, Zhang FY, Liu HX, Mao LH, Yuan L (2023) Biomarkers of Parkinson’s disease: from basic research to clinical practice. Aging Dis. https://doi.org/10.14336/AD.2023.1005
Maas AI et al (2022) Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol 21(11):1004–1060
Margolis RL, Ross CA (2003) Diagnosis of Huntington disease. https://academic.oup.com/clinchem/article/49/10/1726/5641980
Martin SL, Uribe C, Strafella AP (2023) PET imaging of synaptic density in Parkinsonian disorders. J Neurosci Res. https://doi.org/10.1002/jnr.25253
McGinley MP et al (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8):765–779
Mead RJ et al (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22(3):185–212
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29:464. https://doi.org/10.1016/j.ymthe.2020.12.007
Mitchell KJ (2011) The genetics of neurodevelopmental disease. Curr Opin Neurobiol 21(1):197–203
Müller T, Möhr J-D (2019) Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opin Drug Metab Toxicol 15(5):429–435
Nakase T, Naus CC (2004) Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta 1662(1–2):149–158
Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Van Giau V (2020) Type 3 diabetes and its role implications in Alzheimer’s disease. Int J Mol Sci 21(9):3165. https://doi.org/10.3390/IJMS21093165
Núñez-Jaramillo L, Herrera-Solís A, Verónica Herrera-Morales W, Frye RE, Renner M (2021) ADHD: reviewing the causes and evaluating solutions. J Pers Med. https://doi.org/10.3390/jpm11030166
Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780
Okoye C, Obialo-Ibeawuchi CM, Obajeun OA, Sarwar S, Tawfik C, Waleed S, Wasim AU, Mohamoud I, Afolayan AY, Mbaezue RN (2023) Early diagnosis of autism spectrum disorder: a review and analysis of the risks and benefits. Cureus 15:e43226. https://doi.org/10.7759/cureus.43226
Ostrom QT et al (2019) Risk factors for childhood and adult primary brain tumors. Neurooncology 21(11):1357–1375
Perneczky R et al (2023) Anti-amyloid antibody therapies in Alzheimer’s disease. Brain 146(3):842–849
Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res 15(24):7479–7491. https://doi.org/10.1158/1078-0432.CCR-09-0636
Priyadarshini S, Ajroud-Driss S (2023) Update on ALS treatment. Curr Treat Options Neurol 25:1–14
Rexrode KM et al (2022) The impact of sex and gender on stroke. Circ Res 130(4):512–528
Rho JM, Boison D (2022) The metabolic basis of epilepsy. Nat Rev Neurol 18(6):333–347
Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123(3):425–462
Rupprecht CE et al (2022) Rabies in the tropics. Curr Trop Med Rep 9(1):28–39
Scheltens P et al (2021) Alzheimer’s disease. Lancet 397(10284):1577–1590
Schrock LE et al (2015) Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord 30(4):448–471
Shahrizaila N et al (2021) Guillain-Barré syndrome. Lancet 397(10280):1214–1228
Shamsnajafabadi H et al (2023) Current and future landscape in genetic therapies for Leber hereditary optic neuropathy. Cell 12(15):2013
Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43(1):1–7
Shishido E, Ogawa S, Miyata S, Yamamoto M, Inada T, Ozaki N (2019) Application of eye trackers for understanding mental disorders: cases for schizophrenia and autism spectrum disorder. Neuropsychopharmacol Rep 39(2):72–77. https://doi.org/10.1002/NPR2.12046
Simonato M et al (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9(5):277–291
Singh S et al (2022) Focusing the pivotal role of nanotechnology in Huntington’s disease: an insight into the recent advancements. Environ Sci Pollut Res 29(49):73809–73827
Singh A et al (2023) Nanotheranostics: the fabrication of theranostics with nanoparticles and their application to treat the neurological disorders. Recent Patents Nanotechnol. https://doi.org/10.2174/1872210517666230718115651
Sleigh JN et al (2019) Axonal transport and neurological disease. Nat Rev Neurol 15(12):691–703
So RW et al (2019) Application of CRISPR genetic screens to investigate neurological diseases. Mol Neurodegener 14:1–16
Sorboni SG et al (2022) A comprehensive review on the role of the gut microbiome in human neurological disorders. Clin Microbiol Rev 35(1):e00338–e00320
Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19(2):109–117
Tabrizi SJ et al (2022a) Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645–658
Tabrizi SJ et al (2022b) A biological classification of Huntington’s disease: the Integrated Staging System. Lancet Neurol 21(7):632–644
Tfelt-Hansen P (2021) Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. Cephalalgia 41(14):1499–1505
Thakur KT et al (2016) Neurological disorders. Dis Control Prior 4:87–107
Uy CE et al (2021) Autoimmune encephalitis: clinical spectrum and management. Pract Neurol 21(5):412–423
Valenzuela CF et al (2011) Focus on: neurotransmitter systems. Alcohol Res Health 34(1):106
Van Dyck CH et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388(1):9–21
Vaz M, Silvestre S (2020) Alzheimer’s disease: recent treatment strategies. Eur J Pharmacol 887:173554
Vienne-Jumeau A et al (2019) Environmental risk factors of primary brain tumors: a review. Rev Neurol 175(10):664–678
Wahl A, Al-Harthi L (2023) HIV infection of non-classical cells in the brain. Retrovirology 20(1):1
Wang S et al (2022) Status and prospect of novel treatment options toward alveolar and cystic echinococcosis. Acta Trop 226:106252
Wang YTT, Rosa-Neto P, Gauthier S (2023) Advanced brain imaging for the diagnosis of Alzheimer disease. Curr Opin Neurol 36(5):481–490. https://doi.org/10.1097/WCO.0000000000001198
Weintraub D et al (2022) The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol 21(1):89–102
West PK et al (2019) Microglia responses to interleukin-6 and type I interferons in neuroinflammatory disease. Glia 67(10):1821–1841
Wu J et al (2023) Research progress on the treatment of epilepsy with traditional Chinese medicine. Phytomedicine 120:155022
Wyant KJ et al (2017) Huntington’s disease—update on treatments. Curr Neurol Neurosci Rep 17:1–11
Zarei S et al (2015) A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 6:171
Zelena D (2012) Co-regulation and epigenetic dysregulation in schizophrenia and bipolar disorder. In: Patho-epigenetics of disease. Springer, New York, pp 281–347. https://doi.org/10.1007/978-1-4614-3345-3_10/COVER
Zhang Y et al (2022) Toxoplasmosis vaccines: what we have and where to go? NPJ Vaccines 7(1):131
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kumar, P., Zelena, D., Gautam, A. (2023). Neurological Disorders and Challenges in Their Theranostics. In: Gautam, A., Chaudhary, V. (eds) Theranostic Applications of Nanotechnology in Neurological Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-99-9510-3_1
Download citation
DOI: https://doi.org/10.1007/978-981-99-9510-3_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-9509-7
Online ISBN: 978-981-99-9510-3
eBook Packages: MedicineMedicine (R0)